Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma - guidance (TA577)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
24 April 2019

Abstract

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.

Is this guidance up to date?

Next review: 2022

Commercial arrangement

There is a simple discount patient access scheme for brentuximab vedotin. Contact gb.commercial@takeda.com for details.

Guidance development process

How we develop NICE technology appraisal guidance